Phase 3 Results for Olokizumab in RA Patients

No new safety signals identified during the study. Additionally, there were no noticeable efficacy or safety differences between the olokizumab doses.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

Nasonov E, Fatenejad S, Korneva E, et al. Safety and efficacy of olokizumab in a phase 3 trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate—CREDO1 study [abstract L12]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

CR845—an oral, peripherally selective kappa opioid agonist—is currently in Phase 2 trials for the treatment of pruritus, and acute and chronic pain.1 Eighty patients with hip osteoarthritis (OA) or knee OA were randomized to receive treatment with 0.25 mg, 0.5 mg, 1.0 mg or 5.0 mg CR845 twice daily for two weeks. Safety assessment, pharmacokinetics…

Methotrexate and its mechanism of action

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

Rheumatology Drug Updates: Opioid CR845 for OA Pain; RA Treatments in Development

Old Drugs Can Learn New Tricks

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Related Articles